Targeting the checkpoint kinase Chk1 in cancer therapy

Cell Cycle

Volumn 9, Issue 2, 2010, Pages 279-283

  Merry, Callie ^a   Fu, Kang ^a   Wang, Jingna ^a   Yeh, I Ju ^a   Zhang, Youwei ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chk1; Fbx6; Replication checkpoint; Therapy resistance

Indexed keywords

APHIDICOLIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; DNA TOPOISOMERASE INHIBITOR; F BOX PROTEIN; MESYLIC ACID METHYL ESTER;

BREAST TUMOR; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL DIVISION; CELL HYPOXIA; CELL SURVIVAL; DNA REPAIR; ENZYME DEGRADATION; ENZYME REGULATION; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; UBIQUITINATION;

EUKARYOTA;

EID: 74949120032     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.2.10445     Document Type: Review

References (50)

1. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-96.
2. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 2006; 31:402-10.
3. Pacek M, Walter JC. A requirement for MCM7 and Cdc45 in chromosome unwinding during eukaryotic DNA replication. EMBO J 2004; 23:3667-76.
4. Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATRdependent checkpoint. Genes Dev 2005; 19:1040-52.
5. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-45.
6. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature 2007; 450:509-14.
7. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003; 300:1542-8.
8. Kim SM, Kumagai A, Lee J, Dunphy WG. Phosphorylation of Chk1 by ATM- and Rad3-related (ATR) in Xenopus egg extracts requires binding of ATRIP to ATR but not the stable DNA-binding or coiled-coil domains of ATRIP. J Biol Chem 2005; 280:38355-64.
9. Zou L, Cortez D, Elledge SJ. Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev 2002; 16:198-208.
10. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21:4129-39.
11. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59.
12. Kumagai A, Dunphy WG. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell 2000; 6:839-49.
13. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATR-ATRIP complex. Cell 2006; 124:943-55.
14. Wang X, Zou L, Lu T, Bao S, Hurov KE, Hittelman WN, et al. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell 2006; 23:331-41.
15. Delacroix S, Wagner JM, Kobayashi M, Yamamoto K, Karnitz LM. The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev 2007; 21:1472-7.
16. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14:1439-47.
17. Kramer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA, et al. Centrosome-associated Chk1 prevents premature activation of cyclin-BCdk1 kinase. Nat Cell Biol 2004; 6:884-91.
18. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 2005; 19:607-18.
19. Smits VA, Reaper PM, Jackson SP. Rapid PIKKdependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response. Curr Biol 2006; 16:150-9.
20. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008; 132:221-32.
21. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 2007; 27:2572-81.
22. Wilsker D, Petermann E, Helleday T, Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci USA 2008; 105:20752-7.
23. Walker M, Black EJ, Oehler V, Gillespie DA, Scott MT. Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity. Oncogene 2009; 28:2314-23.
24. Oe T, Nakajo N, Katsuragi Y, Okazaki K, Sagata N. Cytoplasmic occurrence of the Chk1/Cdc25 pathway and regulation of Chk1 in Xenopus oocytes. Dev Biol 2001; 229:250-61.
25. Katsuragi Y, Sagata N. Regulation of Chk1 kinase by autoinhibition and ATR-mediated phosphorylation. Mol Biol Cell 2004; 15:1680-9.
26. Chen P, Luo C, Deng Y, Ryan K, Register J, Margosiak S, et al. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 2000; 100:681-92.
27. Chen Y, Caldwell JM, Pereira E, Baker RW, Sanchez Y. ATRMec1 Phosphorylation-independent Activation of Chk1 in Vivo. J Biol Chem 2009; 284:182-90.
28. Kosoy A, O'Connell MJ. Regulation of Chk1 by its C-terminal domain. Mol Biol Cell 2008; 19:4546-53.
29. Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 2007; 9:391-401.
30. Feng JM, Zhu H, Zhang XW, Ding J, Miao ZH. Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity. Cancer Biol Ther 2008; 7:1726-31.
31. Jurvansuu J, Fragkos M, Ingemarsdotter C, Beard P. Chk1 Instability Is Coupled to Mitotic Cell Death of p53-deficient Cells in Response to Virus-induced DNA Damage Signaling. J Mol Biol 2007; 372:397-406.
32. Leung-Pineda V, Huh J, Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res 2009; 69:2630-7.
33. Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell 2009; 35:442-53.
34. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005; 19:1162-74.
35. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38.
36. den Elzen NR, O'Connell MJ. Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1. EMBO J 2004; 23:908-18.
37. Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 2001; 61:4990-3.
38. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y. The radioresistance to killing of A1-5 cells derives from activation of the Chk1 pathway. J Biol Chem 2001; 276:17693-8.
39. Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer 2003; 105:617-24.
40. Ng CP, Lee HC, Ho CW, Arooz T, Siu WY, Lau A, et al. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem 2004; 279:8808-19.
41. Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O. Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene 2005; 24:1973-81.
42. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005; 65:780-6.
43. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, et al. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007; 6:2571-8.
44. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6:45-59.
45. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
46. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9.
47. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005; 4:131-9.
48. Madoz-Gurpide J, Canamero M, Sanchez L, Solano J, Alfonso P, Casal JI. A proteomic analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics 2007; 6:2150-64.
49. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 2007; 67:6574-81.
50. Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res 2008; 10:81.